Engineered Antibodies Act As Targeted Therapies in Cancer Treatment

Overview

Journal Indian J Pediatr

Specialty Pediatrics

Date 2006 Jan 5

PMID 16391449

Citations 2

Authors

Mani Mohindru

Amit Verma

Affiliations

Soon will be listed here.

Abstract

Over the last two decades cancer cure rates have not gone up as expected, and the effectiveness of chemotherapy has reached a plateau. This has prompted a search for targeted therapies with higher efficacy and lesser toxicities. Monoclonal antibodies against cancer cells offer targeted therapies with little or no toxicities against normal tissues. In this review we will discuss the concepts behind the development of monoclonal antibodies in cancer and their present status in the clinic. Specifically, we will discuss the clinical use of Rituximab (RituxanO), Trastuzumab (HerceptinO) and Bevacizumab (AvastinO) in various cancers and the key clinical trials that have led to their incorporation in cancer therapeutics.

Citing Articles

In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.

Guo D, Han J, Li Y, Liu Z, Lu S, Ren H Oncol Lett. 2012; 4(2):311-318.

PMID: 22844376 PMC: 3402730. DOI: 10.3892/ol.2012.733.

Immunotherapy for pediatric cancer.

Grupp S, Verneris M, Sondel P, Cooper L Biol Blood Marrow Transplant. 2008; 14(1 Suppl 1):33-43.

PMID: 18162219 PMC: 2888484. DOI: 10.1016/j.bbmt.2007.10.014.

References

Witzig T, White C, Gordon L, Wiseman G, Emmanouilides C, Murray J . Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol. 2003; 21(7):1263-70. DOI: 10.1200/JCO.2003.08.043. View

Kazkaz H, Isenberg D . Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol. 2004; 4(4):398-402. DOI: 10.1016/j.coph.2004.03.006. View

Vose J, Link B, Grossbard M, Czuczman M, Grillo-Lopez A, Gilman P . Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001; 19(2):389-97. DOI: 10.1200/JCO.2001.19.2.389. View

Keating M, Flinn I, Jain V, Binet J, Hillmen P, Byrd J . Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002; 99(10):3554-61. DOI: 10.1182/blood.v99.10.3554. View

Witzig T, Gordon L, Cabanillas F, Czuczman M, Emmanouilides C, Joyce R . Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20(10):2453-63. DOI: 10.1200/JCO.2002.11.076. View

Osterborg A, Mellstedt H, Keating M . Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Med Oncol. 2002; 19 Suppl:S21-6. DOI: 10.1385/mo:19:2s:s21. View

Moreton P, Hillmen P . Alemtuzumab therapy in B-cell lymphoproliferative disorders. Semin Oncol. 2003; 30(4):493-501. DOI: 10.1016/s0093-7754(03)00253-7. View

Smith M . Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003; 22(47):7359-68. DOI: 10.1038/sj.onc.1206939. View

Avivi I, Robinson S, Goldstone A . Clinical use of rituximab in haematological malignancies. Br J Cancer. 2003; 89(8):1389-94. PMC: 2394352. DOI: 10.1038/sj.bjc.6601187. View

10.

Yang J, Haworth L, Sherry R, Hwu P, Schwartzentruber D, Topalian S . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349(5):427-34. PMC: 2275324. DOI: 10.1056/NEJMoa021491. View

11.

Horwitz S, Negrin R, Blume K, Breslin S, Stuart M, Stockerl-Goldstein K . Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2003; 103(3):777-83. DOI: 10.1182/blood-2003-04-1257. View

12.

Faderl S, Thomas D, OBrien S, Garcia-Manero G, Kantarjian H, Giles F . Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003; 101(9):3413-5. DOI: 10.1182/blood-2002-07-1952. View

13.

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

14.

Hainsworth J, Litchy S, Barton J, Houston G, Hermann R, Bradof J . Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003; 21(9):1746-51. DOI: 10.1200/JCO.2003.09.027. View

15.

Kaminski M, Zelenetz A, Press O, Saleh M, Leonard J, Fehrenbacher L . Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001; 19(19):3918-28. DOI: 10.1200/JCO.2001.19.19.3918. View

16.

McLaughlin P, Hagemeister F, Rodriguez M, Sarris A, Pate O, Younes A . Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol. 2001; 27(6 Suppl 12):37-41. View

17.

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4):235-42. DOI: 10.1056/NEJMoa011795. View

18.

Herrera L, Farah R, Pellegrini V, Aquino D, Sandler E, Buchanan G . Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000; 14(5):853-8. DOI: 10.1038/sj.leu.2401779. View